Invokana Lawsuit Avers Link to Diabetic Ketoacidosis

April 25, 2016 – – TheProductLawyers.com comments on a lawsuit against Janssen Pharmaceuticals, the makers of Invokana and a branch of Johnson and Johnson Corporation. The plaintiff avers that shortly after beginning a prescribed regimen of the drug for the management of her type-2 diabetes, she suffered injury and developed diabetic ketoacidosis. Her suit was filed in the District Court of New Jersey in late 2015. As a result, she seeks $10 million dollars in damages and compensation for medical bills, injury, and directly related future medical treatments.

After beginning a maintenance regimen for her type-2 diabetes in October of 2013, the Texas woman asserted that she began experiencing adverse reactions to the drug. Upon her request, her doctor tested her for diabetic ketoacidosis (DKA). Not only was she positive for DKA, but she was also suffering from extensive and severe damage to her kidneys.

Invokana and other drugs of its class are known as SGLT2 class inhibitor drugs. They assist in the maintenance of blood glucose levels by diverting a portion of excess sugar from the blood to the kidneys. The reuptake of the glucose is prevented and it is eliminated via urination. While this process is incredibly effective, it has also been linked to severe stress of the entire renal system, potential damage, infection, and DKA.

While she immediately ceased taking Invokana, the damage to her kidneys is both permanent and severe. Diabetic ketoacidosis is a condition usually associated with type-1 diabetes, but is not unknown among those with insulin-resistant diabetes. Rather, it is linked with a lack of available insulin, by which the body processes glucose in the bloodstream. As a result, fat is released from reserves, taken up by the liver, and the kidneys begin producing blood acids called ketones.

The U.S. FDA has issued advisory statements regarding the heightened risk of DKA and other complications in association with Invokana maintenance regimens. After receiving adverse event reports that link this condition with use of the drug, the pharmaceutical companies that manufacture and distribute Invokana are compelled to heighten the vigor with which they warn of such potential side effects.

For more information about the Invokana lawsuits, or this press release, please contact TheProductLawyers.com on 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60009500